Journal Home
Search for

Volume 41, Issue 1, Pages 33-38 (February 2007)


View previous. 4 of 9 View next.

S-(+)-fenfluramine-induced nociceptive behavior in mice: Involvement of interactions between spinal serotonin and substance P systems

Koichi Tan-NoaCorresponding Author Informationemail address, Katsuaki Takahashia, Masakazu Shimodaa, Mai Sugawaraa, Osamu Nakagawasaia, Fukie Niijimaa, Takumi Satob, Susumu Satohb, Takeshi Tadanoa

Received 12 August 2006; accepted 11 October 2006. published online 01 December 2006.

Abstract 

Intrathecal (i.t.) administration into mice of S-(+)-fenfluramine (0.01–0.1nmol), a serotonin (5-hydroxytryptamine, 5-HT) releaser, produced a behavioral response consisting of scratching, biting and licking. Here, we report the behavioral characteristics and the involvement of interactions between 5-HT and substance P (SP) systems in the S-(+)-fenfluramine-induced behavioral response. The S-(+)-fenfluramine-induced behavioral response peaked at 5–15min and almost disappeared at 20min after injection. The behavior induced by S-(+)-fenfluramine (0.1nmol) was dose-dependently inhibited by an intraperitoneal injection of morphine (0.02–0.5mg/kg), suggesting that the behavioral response is related to nociception. The S-(+)-fenfluramine-induced nociceptive behavior was significantly inhibited by pretreatment with 5-HT antiserum and co-administration of ketanserin, a selective 5-HT2 receptor antagonist. However, WAY-100635, a selective 5-HT1A receptor antagonist, and ramosetron, a selective 5-HT3 receptor antagonist, were not active. On the other hand, SP antiserum and RP67580, a selective neurokinin-1 (NK1) receptor antagonist, significantly inhibited S-(+)-fenfluramine-induced nociceptive behavior. These results suggest that i.t.-administered S-(+)-fenfluramine releases SP through the activation of 5-HT2 receptors subsequent to 5-HT release, and, as a result, produces nociceptive behavior.

Article Outline

Abstract

1. Introduction

2. Materials and methods

2.1. Animals

2.2. Intrathecal injections

2.3. Behavioral observation

2.4. Drugs and antisera

2.5. Statistics

3. Results

3.1. Behavioral response induced by i.t.-administered S-(+)-fenfluramine

3.2. Effects of 5-HT antiserum and 5-HT receptor antagonists on S-(+)-fenfluramine-induced nociceptive behavior

3.3. Effects of SP antiserum and RP67580 on S-(+)-fenfluramine-induced nociceptive behavior

4. Discussion

Acknowledgment

References

Copyright

1. Introduction 

return to Article Outline

Several lines of evidence suggest that the neurotransmitter serotonin (5-hydroxytryptamine, 5-HT) plays an important role in the modulation of nociceptive transmission and that the major site of action of 5-HT is the spinal cord (for review, see Fields et al., 1991, Furst, 1999). Although multiple 5-HT receptor subtypes have been defined in the central nervous system (for review, see Barnes and Sharp, 1999), at least four types of 5-HT receptors (5-HT1, 5-HT2, 5-HT3 and 5-HT4) with several subtypes have been identified in the spinal cord (for a review, see Hoyer et al., 1994).

Substance P (SP) has been proposed to be an important neurotransmitter in primary sensory neurons involved in nociception (for a review, see Sakurada et al., 1997) and coexisted with 5-HT in bulbospinal neurons and SP-containing neurons which project to the raphe nuclei, the major site of 5-HT cell bodies (Johansson et al., 1981). Behavioral studies in mice have indicated that intrathecal (i.t.) administration of 5-HT (2μg) (Eide and Hole, 1991a) or a selective 5-HT2 receptor agonist (Eide and Hole, 1991b, Mjellem et al., 1993) produces the characteristic nociceptive behavior consisting of hindlimb scratching directed toward the flank, biting and/or licking of the hindpaw and the tail resembling the behaviors induced by neurokinin-1 (NK1) receptor agonists such as SP (Takahashi et al., 1987, Sakurada et al., 1991). The nociceptive behavior induced by 5-HT (2μg) is reduced by i.t. pretreatment with spantide, a non-selective NK1 receptor antagonist (Eide and Hole, 1991a). In contrast, i.t. administration of 5-HT (20μg) or the selective 5-HT1 receptor agonists produces the antinociceptive effect as measured by the mouse tail-flick test, which is reduced by pretreatment with SP (Eide and Hole, 1991a). These reports seem to indicate functional interactions between 5-HT and SP in the regulation of nociceptive transmission in the mouse spinal cord. However, the effects of using 5-HT receptor agonists do not necessarily reflect the physiological significance of the spinal interactions between 5-HT and SP systems in nociceptive transmission.

Thus, in the present study, we first examined the effect of i.t. administration into mice of S-(+)-fenfluramine, which releases 5-HT from axon terminals; as a result, S-(+)-fenfluramine produced the behavioral response consisting of scratching, biting and licking through the activation of 5-HT2 receptors subsequent to 5-HT release. We also examined the effects of a selective NK1 receptor antagonist and SP antiserum on the S-(+)-fenfluramine-induced behavioral response in order to clarify the physiological significance of the spinal interactions between 5-HT and SP systems in nociceptive transmission.

2. Materials and methods 

return to Article Outline

2.1. Animals 

Experiments were performed in male ddY mice (Japan SLC, Hamamatsu, Japan) weighing 22–25g and maintained on a 12h light/dark cycle (light 8:00 a.m.–8:00 p.m.) with constant temperature (23±1°C) and relative humidity (55±5%). Groups of 10 mice were used only once in each experiments.

2.2. Intrathecal injections 

I.t. injections were made in unanaesthetized mice in the L5, L6 intervertebral space as described by Hylden and Wilcox (1980). Briefly, a volume of 5μL was administered i.t. with a 28 gauge needle connected to a 50μL Hamilton microsyringe, the animal being lightly restrained to maintain the position of the needle. Puncture of the dura was indicated behaviorally by a slight flick of the tail.

2.3. Behavioral observation 

Approximately 60min before the i.t. injection, mice were adapted to an individual transparent cage (22.0×15.0×12.5cm) which was also used as the observation chamber after injection. Immediately after the i.t. injection of S-(+)-fenfluramine, the mice were returned to their cage and the accumulated response time of hindlimb scratching directed toward the flank, biting and/or licking of the hindpaw and the tail was measured for 20min. The measurement of the behavioral responses was performed blind, i.e., the observer had no information as to group designation.

2.4. Drugs and antisera 

The following drugs and chemicals were used: S-(+)-fenfluramine, ketanserin tartrate, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclohexanecarboxamide maleate (WAY-100635) (Sigma Chemical Co., St. Louis, MO, USA), (3aR,7aR)-octahydro-2-[1-imino-2-(2-methoxyphenyl)ethyl]-7,7-diphenyl-4H-isoindol (RP 67580) (Tocris, Cookson, UK), 5-HT antiserum (Progen Biotechnik GmbH, Heidelberg, Germany), SP antiserum (Chemicon International, Temecula,CA, USA) and morphine hydrochloride (Sankyo, Tokyo, Japan). Ramosetron hydrochloride was provided from Yamanouchi Pharmaceutical Co. (Tsukuba, Japan). For i.t. injections, all compounds, except for RP 67580, were dissolved in Ringer solution. RP 67580 was dissolved in Ringer solution containing 7.5% dimethylsulfoxide. When the effects of 5-HT or NK1 receptor-related antagonists were tested, they were co-injected with S-(+)-fenfluramine in a volume of 5μL to prevent damage due to repeated i.t. administration. Antiserum against 5-HT or SP was diluted in Ringer solution and injected i.t. 5min prior to injection of S-(+)-fenfluramine. Morphine was dissolved in saline and administered intraperitoneally (i.p.) 5min prior to injection of S-(+)-fenfluramine.

2.5. Statistics 

The results are presented as the means and SEM The ID50 values with 95% confidence limits were calculated for reduction in the S-(+)-fenfluramine-induced scratching, biting and licking response by computer-associated curve-fitting program (GraphPad Prism, Graphpad Software, Inc., San Diego, CA, USA). Statistical evaluations were performed using Mann–Whitny U-test (two-tailed) in the time course experiment. The comparisons of dose- and dilution-dependent differences of the effects of drugs and antisera on S-(+)-fenfluramine-induced behavior were determined by Fisher’s PLSD post hoc test for multiple comparisons after analysis of variance (ANOVA). In all statistical comparisons, P<0.05 was used as the criterion for statistical significance.

3. Results 

return to Article Outline

3.1. Behavioral response induced by i.t.-administered S-(+)-fenfluramine 

The i.t. administration of S-(+)-fenfluramine (0.1nmol) produced a characteristic behavioral response consisting of scratching, biting and licking, which peaked at 5–15min and almost disappeared at 20min after injection (Fig. 1b). As seen in Fig. 1a, a dose-dependent increase in the total time of scratching, biting and licking was observed following i.t. administration of S-(+)-fenfluramine in doses ranging from 0.01–0.1nmol. However, no further increase in the behavioral response was produced by injection of S-(+)-fenfluramine at a higher dose of 0.3nmol. In further experiments, 0.1nmol of S-(+)-fenfluramine and a 20min observation time were therefore used in combination with various drugs and antisera to test their inhibitory actions. It was then examined whether S-(+)-fenfluramine-induced behavior is reversed by morphine. As shown in Fig. 2, pretreatment with morphine (0.02–0.5mg/kg, i.p.) inhibited S-(+)-fenfluramine-induced behavior in a dose-dependent manner with an ID50 value of 0.19 (0.19–0.20)mg/kg, suggesting that the behavioral response is related to nociception.


View full-size image.

Fig. 1. (a) Effects of varying doses of i.t.-administered S-(+)-fenfluramine in mice. The duration of scratching, biting and licking induced by S-(+)-fenfluramine or Ringer was determined during a 20min period starting immediately after injection. (b) Time-courses of the scratching, biting and licking response induced by i.t. injection of S-(+)-fenfluramine (0.1nmol) or Ringer alone. The ordinate shows the total time of scratching, biting and licking response which occurred during each 5min of measurement. These data are given as the means and SEM for groups of 10 mice. ∗∗P<0.01 when compared with Ringer controls.



View full-size image.

Fig. 2. Effect of morphine on S-(+)-fenfluramine-induced scratching, biting and licking response in mice. Morphine was administered i.p. 5min prior to injection of S-(+)-fenfluramine (0.1nmol). The duration of scratching, biting and licking induced by S-(+)-fenfluramine was determined during a 20min period starting immediately after i.t. injection. These data are given as the means and SEM for groups of 10 mice. ∗∗P<0.01 when compared with S-(+)-fenfluramine alone.


3.2. Effects of 5-HT antiserum and 5-HT receptor antagonists on S-(+)-fenfluramine-induced nociceptive behavior 

To test whether 5-HT release is involved in the effects of S-(+)-fenfluramine, the effect of pretreatment with 5-HT antiserum was examined. When administered i.t. 5min before the injection of S-(+)-fenfluramine, 5-HT antiserum (1:1250–1:50) reduced S-(+)-fenfluramine-induced nociceptive behavior in a dilution-related manner (Fig. 3a). Ketanserin (0.3–3.0nmol), a selective 5-HT2 receptor antagonist, co-administered i.t. with S-(+)-fenfluramine also caused a dose-dependent inhibition of S-(+)-fenfluramine-induced nociceptive behavior with an ID50 value of 0.68 (0.60–0.77)nmol (Fig. 3b).


View full-size image.

Fig. 3. Effect of 5-HT antiserum and ketanserin on S-(+)-fenfluramine-induced nociceptive behavior in mice. (a) The antiserum against 5-HT or Ringer was administered i.t. 5min prior to injection of S-(+)-fenfluramine (0.1nmol). The duration of scratching, biting and licking induced by S-(+)-fenfluramine was determined during a 20min period starting immediately after i.t. injection of S-(+)-fenfluramine. (b) Ketanserin was co-administered i.t. with S-(+)-fenfluramine (0.1nmol). The duration of scratching, biting and licking induced by S-(+)-fenfluramine was determined during a 20min period starting immediately after injection. These data are given as the means and SEM for groups of 10 mice. (a) ∗∗P<0.01 when compared with Ringer plus S-(+)-fenfluramine-treated group. (b) ∗∗P<0.01 when compared with S-(+)-fenfluramine alone.


A single administration of 1.0nmol, but not 0.5nmol of WAY-100635, a selective 5-HT1A receptor antagonist, caused a significant nociceptive behavior under conditions tested (data not shown). Therefore, 0.5 nmol of WAY-100635 was applied in combination with S-(+)-fenfluramine. As shown in Table 1, WAY-100635 did not inhibit S-(+)-fenfluramine-induced nociceptive behavior. Moreover, ramosetron, a selective 5-HT3 receptor antagonist, even at a comparatively high dose of 4nmol had no effect on S-(+)-fenfluramine-induced nociceptive behavior (Table 1).

Table 1.

Effects of WAY-100635 and ramosetron on S-(+)-fenfluramine-induced nociceptive behavior in mice

Agents
Behavioral response (s/20min)
Ringer41.6±4.1
WAY-100635 (0.5nmol)43.3±3.1
Ramosetron (4.0nmol)37.1±3.7

Each agent was co-administered i.t. with S-(+)-fenfluramine (0.1nmol). The duration of scratching, biting and licking induced by S-(+)-fenfluramine was determined during a 20min period starting immediately after i.t. injection. These data are given as the means±SEM for groups of 10 mice.

3.3. Effects of SP antiserum and RP67580 on S-(+)-fenfluramine-induced nociceptive behavior 

As shown in Fig. 4a, pretreatment with SP antiserum (1:4096–1:1024) reduced S-(+)-fenfluramine-induced nociceptive behavior in a dilution-related manner, similar to that of 5-HT antiserum. In addition, RP67580 (0.5–8nmol), a selective NK1 receptor antagonist, produced a dose-dependent inhibition of S-(+)-fenfluramine-induced nociceptive behavior with an ID50 value of 5.12 (4.89–5.35)nmol (Fig. 4b).


View full-size image.

Fig. 4. Effect of SP antiserum and RP67580 on S-(+)-fenfluramine-induced nociceptive behavior in mice. (a) The antiserum against SP or Ringer was administered i.t. 5min prior to injection of S-(+)-fenfluramine (0.1nmol). The duration of scratching, biting and licking induced by S-(+)-fenfluramine was determined during a 20min period starting immediately after i.t. injection of S-(+)-fenfluramine. (b) RP67580 was co-administered i.t. with S-(+)-fenfluramine (0.1nmol). The duration of scratching, biting and licking induced by S-(+)-fenfluramine was determined during a 20min period starting immediately after injection. These data are given as the means and SEM for groups of 10 mice. (a) ∗∗P<0.01 when compared with Ringer plus S-(+)-fenfluramine-treated group. (b) ∗∗P<0.01 when compared with S-(+)-fenfluramine alone.


4. Discussion 

return to Article Outline

The present data clearly show that i.t.-administered S-(+)-fenfluramine (0.01–0.1nmol) produced nociceptive behavior consisting of scratching, biting and licking, which peaked at 5–15min and almost disappeared at 20min after injection. S-(+)-Fenfluramine (0.1nmol)-induced nociceptive behavior was dose-dependently reduced by quite small doses of morphine (0.02–0.5mg/kg, i.p.). These results are similar to our previously reported findings in which i.t. administration of SP in mice produced nociceptive behavior (Takahashi et al., 1987), though the peak time effect of S-(+)-fenfluramine was much later than that of SP-induced nociceptive behavior, which peaked at 0–5min following i.t. administration.

It is known that the spinal 5-HT system is involved in both inhibition and facilitation of nociceptive transmission (for review, see Eide and Hole, 1993). Electrophysiological studies have provided evidence that 5-HT1A and 5-HT2 receptors mediate inhibitory and excitatory effects of 5-HT on neuronal excitation, respectively (El-Yassir et al., 1988, Araneda and Andrade, 1991, Brandao et al., 1991). The different responses after stimulation of 5-HT1A and 5-HT2 receptors have been explained by the fact that these receptors couple to different intracellular signaling systems. The 5-HT1A receptors inhibit adenylate cyclase activity (De Vivo and Maayani, 1986), whereas the 5-HT2 receptors activate phospholipase C and the inositol triphosphate (IP3) pathway, leading to a release of intracellular calcium and subsequent neuronal excitation (for review, see Fozard, 1987). These facts indicate that the divergence of the 5-HT system on the spinal regulation in nociceptive transmission may be also explained by the difference of 5-HT receptors; activation of 5-HT1A and 5-HT2 receptors produces inhibition and facilitation in the spinal nociceptive transmission, respectively. Dual actions in facilitating and inhibiting the spinal nociceptive transmission are not limited to 5-HT; they are also observed in spermine (Tan-No et al., 2000, Tan-No et al., 2003), dynorphins (Tan-No et al., 1996, Tan-No et al., 2002, Tan-No et al., 2005a, Tan-No et al., 2005b) and nociceptin (Sakurada et al., 1999). In the present study, S-(+)-fenfluramine-induced nociceptive behavior was significantly reduced by pretreatment with 5-HT antiserum and co-administration of ketanserin but not with WAY-100635 or ramosetron. In mice, i.t. administration of (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI), a selective 5-HT2 receptor agonist, produces nociceptive behavior (Eide and Hole, 1991b, Mjellem et al., 1993) which is similar to that seen after i.t. administration of S-(+)-fenfluramine and SP. Taken together with these previous reports, the present results suggest that S-(+)-fenfluramine produces nociceptive behavior through the activation of 5-HT2 receptors following 5-HT release. The present study also showed that the dose–response for S-(+)-fenfluramine-induced nociceptive behavior was a bell-shaped pattern. It has been reported that i.t. administration of (+)-8-hydroxy-2-(di-n-propylamino)-tetralin ((+)-8-OH-DPAT), a selective 5-HT1A receptor agonist, produces an antinociceptive effect in the mouse tail-flick test (Eide and Hole, 1991a, Eide and Hole, 1991b), and inhibits nociceptive behavior elicited by N-methyl-d-aspartate (NMDA) and α-amino-3-hydroxy-5-methyl-4-isoxazole-proprionic acid (AMPA) (Mjellem et al., 1993). One possible explanation for the decreased effect of S-(+)-fenfluramine at a higher dose (0.3nmol) is that activation for 5-HT1A receptors through release of 5-HT by i.t. administration of S-(+)-fenfluramine at a higher dose has an inhibitory effect on S-(+)-fenfluramine-induced nociceptive behavior.

We also demonstrated that S-(+)-fenfluramine-induced nociceptive behavior was significantly inhibited by RP67580. It has recently been reported that stimulation of spinal 5-HT2A/2C receptors by DOI potentiates the capsaicin-induced release of SP-like immunoreactivity in the rat dorsal horn in an experiment using microdialysis (Bertelsen et al., 2003). It is, therefore, reasonable to presume that S-(+)-fenfluramine-induced nociceptive behavior may be due to stimulation of NK1 receptors indirectly, possibly through SP release. This interpretation is supported by an additional data that pretreatment with SP antiserum resulted in a significant reduction of the S-(+)-fenfluramine-induced nociceptive behavior. Similar observations have been obtained by using SP antiserum in nociceptive behavior elicited by i.t. injection of pilocarpine (Sakurada et al., 1993), high-dose morphine (Sakurada et al., 1996) and extremely low-dose nociceptin (Sakurada et al., 1999).

In conclusion, we have presented evidence that i.t.-administered S-(+)-fenfluramine produces nociceptive behavior. The mechanism seems to be that S-(+)-fenfluramine activates 5-HT2 receptors following 5-HT release and facilitates SP release, which subsequently acts on NK1 receptors to produce the spinal cord-mediated nociceptive behavior.

Acknowledgements 

return to Article Outline

This study was supported in part by a Grant-in-Aid for Scientific Research (C) (No. 18613016) from the Japan Society for the Promotion of Science to KT, and a Grant-in-Aid for High Technology Research Program from the Ministry of Education, Culture, Sports, Science and Technology, Japan.

References 

return to Article Outline

Araneda and Andrade, 1991. 1.Araneda R, Andrade R. 5-Hydroxytryptamine2 and 5-hydroxytryptamine1A receptors mediated opposing responses on membrane excitability in rat association cortex. Neuroscience. 1991;40:399–412. MEDLINE | CrossRef

Barnes and Sharp, 1999. 2.Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 1999;38:1083–1152. MEDLINE | CrossRef

Bertelsen et al., 2003. 3.Bertelsen AK, Afrah AW, Gustafsson H, Tjølsen A, Hole K, Stiller C-O. Stimulation of spinal 5-HT2A/2C receptors potentiates the capsaicin-induced in vivo release of substance P-like immunoreactivity in the rat dorsal horn. Brain Research. 2003;987:10–16.

Brandao et al., 1991. 4.Brandao ML, Lopez-Garcia JA, Graeff FG, Roberts MHT. Electrophysiological evidence for excitatory 5-HT2 and depressant 5-HT1A receptors on neurons of the rat midbrain tectum. Brain Research. 1991;556:259–266.

De Vivo and Maayani, 1986. 5.De Vivo M, Maayani S. Characterization of the 5-hydroxytryptamine1A receptor-mediated inhibition of forskolin-stimulated adenylate cyclase activity in guinea pig and rat hippocampal membranes. Journal of Pharmacology and Experimental Therapeutics. 1986;238:248–253.

Eide and Hole, 1991a. 6.Eide PK, Hole K. Interactions between serotonin and substance P in the spinal regulation of nociception. Brain Research. 1991;550:225–230.

Eide and Hole, 1991b. 7.Eide PK, Hole K. Different role of 5-HT1A and 5-HT2 receptors in spinal cord in the control of nociceptive responsiveness. Neuropharmacology. 1991;30:727–731. MEDLINE | CrossRef

Eide and Hole, 1993. 8.Eide PK, Hole K. The role of 5-hydroxytryptamine (5-HT) receptor subtypes and plasticity in the 5-HT systems in the regulation of nociceptive sensitivity. Cephalalgia. 1993;13:75–85. MEDLINE

El-Yassir et al., 1988. 9.El-Yassir N, Fleetwood-Walker SM, Mitchell R. Heterogeneous effects of serotonin in the dorsal horn of rat: the involvement of 5-HT1 receptor subtypes. Brain Research. 1988;456:147–158.

Fields et al., 1991. 10.Fields HL, Heinricher MM, Mason P. Neurotransmitters in nociceptive modulatory circuits. Annual Review of Neuroscience. 1991;14:219–245.

Fozard, 1987. 11.Fozard JR. 5-HT: the enigma variations. Trends in Pharmacological Sciences. 1987;8:501–506. CrossRef

Furst, 1999. 12.Furst S. Transmitters involved in antinociception in the spinal cord. Brain Research Bulletin. 1999;48:129–141. MEDLINE | CrossRef

Hoyer et al., 1994. 13.Hoyer D, Clarke DE, Fozard JR, Harting PR, Martin GR, Mylecharane EJ, et al. International union of pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacological Review. 1994;46:157–203.

Hylden and Wilcox, 1980. 14.Hylden JLK, Wilcox GL. Intrathecal morphine in mice, a new technique. European Journal Pharmacology. 1980;67:313–316.

Johansson et al., 1981. 15.Johansson O, Hökfelt T, Pernow B, Jeffcoate SL, White N, Steinbusch HWM, et al. Immunohistochemical support for three putative transmitters in one neuron: coexistence of 5-hydroxytryptamine, substance P- and thyrotropin releasing hormone-like immunoreactivity in medullary neurons projecting to the spinal cord. Neuroscience. 1981;6:1857–1881. MEDLINE | CrossRef

Mjellem et al., 1993. 16.Mjellem N, Lund A, Hole K. Different functions of spinal 5-HT1A and 5-HT2 receptor subtypes in modulating behaviour induced by excitatory amino acid receptor agonists in mice. Brain Research. 1993;626:78–82.

Sakurada et al., 1991. 17.Sakurada T, Yamada T, Tan-No K, Manome Y, Sakurada S, Kisara K, et al. Differential effects of substance P analogs on neurokinin 1 receptor agonists in the mouse spinal cord. Journal of Pharmacology and Experimental Therapeutics. 1991;259:205–210.

Sakurada et al., 1993. 18.Sakurada T, Manome Y, Tan-No K, Matsunaga Y, Sakurada S, Kisara K. Possible involvement of the spinal substance P system in pilocarpine-induced scratching in mice. Pharmacology Biochemistry and Behavior. 1993;44:439–445. MEDLINE | CrossRef

Sakurada et al., 1996. 19.Sakurada T, Wako K, Sakurada C, Manome Y, Tan-No K, Sakurada S, et al. Spinally-mediated behavioural responses evoked by intrathecal high-dose morphine: possible involvement of substance P in the mouse spinal cord. Brain Research. 1996;724:213–221.

Sakurada et al., 1997. 20.Sakurada T, Sakurada C, Tan-No K, Kisara K. Neurokinin receptor antagonists. Therapeutic potential in the treatment of pain syndromes. CNS Drugs. 1997;8:436–447. CrossRef

Sakurada et al., 1999. 21.Sakurada T, Katsuyama S, Sakurada S, Inoue M, Tan-No K, Kisara K, et al. Nociceptin-induced scratching, biting and licking in mice: involvement of spinal NK1 receptors. British Journal of Pharmacology. 1999;127:1712–1718. MEDLINE | CrossRef

Takahashi et al., 1987. 22.Takahashi K, Sakurada T, Sakurada S, Kuwahara H, Yonezawa A, Ando R, et al. Behavioural characterization of substance P-induced nociceptive response in mice. Neuropharmacology. 1987;26:1289–1293. MEDLINE | CrossRef

Tan-No et al., 1996. 23.Tan-No K, Taira A, Sakurada T, Inoue M, Sakurada S, Tadano T, et al. Inhibition of dynorphin-converting enzymes prolongs the antinociceptive effect of intrathecally administered dynorphin in the mouse formalin test. European Journal of Pharmacology. 1996;314:61–67. MEDLINE | CrossRef

Tan-No et al., 2000. 24.Tan-No K, Taira A, Wako K, Niijima F, Nakagawasai O, Tadano T, et al. Intrathecally administered spermine produces the scratching, biting and licking behavior in mice. Pain. 2000;86:55–61. Abstract | Full Text | Full-Text PDF (377 KB) | CrossRef

Tan-No et al., 2002. 25.Tan-No K, Esashi A, Nakagawasai O, Niijima F, Tadano T, Sakurada C, et al. Intrathecally administered big dynorphin, a prodynorphin-derived peptide, produces nociceptive behavior through an N-methyl-d-aspartate receptor mechanism. Brain Research. 2002;952:7–14.

Tan-No et al., 2003. 26.Tan-No K, Esashi A, Taira A, Nakagawasai O, Niijima F, Sakurada C, et al. Intrathecal spermine and spermidine at high-doses induce antinociceptive effects in the mouse capsaicin test. Biogenic Amines. 2003;17:313–320.

Tan-No et al., 2005a. 27.Tan-No K, Takahashi H, Nakagawasai O, Niijima F, Sato T, Satoh S, et al. Pronociceptive role of dynorphins in uninjured animals: N-ethylmaleimide-induced nociceptive behavior mediated through inhibition of dynorphin degradation. Pain. 2005;113:301–309. Abstract | Full Text | Full-Text PDF (490 KB) | CrossRef

Tan-No et al., 2005b. 28.Tan-No K, Taira A, Nakagawasai O, Niijima F, Demuth H-U, Silberring J, et al. Differential effects of N-peptidyl-O-acyl hydroxylamines on dynorphin-induced antinociception in the mouse capsaicin test. Neuropeptides. 2005;39:569–573. Abstract | Full Text | Full-Text PDF (262 KB) | CrossRef

a Department of Pharmacology, Tohoku Pharmaceutical University, 4-4-1 Komatsushima, Aoba-ku, Sendai 981-8558, Japan

b Department of Pharmacology and Pharmacotherapy, Nihon Pharmaceutical University, Kitaadachi-gun, Saitama 362-0806, Japan

Corresponding Author InformationCorresponding author. Tel.: +81 22 727 0123; fax: +81 22 275 2013.

PII: S0143-4179(06)00143-0

doi:10.1016/j.npep.2006.10.003


View previous. 4 of 9 View next.